The key words in your piece are 'Subject to the customer meeting its contractual revenue targets' That means KMK are one step removed from the end users and will probably have little control over sales as a result. Sales of £4m ish and a market cap of £50m-a lot of blue sky to gaze into here. Cash burn very heavy so big sales need to come in-an event that has been in the offing for a while. Jury out for me but there is a huge amount of hope in the market cap.Having a profit warning so soon after IPO highlights the usual problem with technology companies-sales are driven by others in the distribution channel so not in your gift.
http://uk.advfn.com/news/UKREG/2014/article/63392224 I thought today's results were encouraging. I was particularly encouraged by the 122% growth in revenue, the fact that the company still has no debt, the rate of contract wins and the size of them. "In early April 2014, we announced a contract to supply medical imaging modules to a SME manufacturer of x-ray diagnostics and analysis equipment in China. The contract provides for revenues of $1.4m in the current financial year and $10.2m in the next financial year, and the overall value of the contract over the seven years is up to $159m, subject to the customer meeting its contractual revenue targets." There is also the fact that "The appetite for Kromek's components, systems and solutions in each of our target markets is increasing." Hopefully this is all a sign of strong progress in the coming years.
25 Aug '14
Like 'truthfactory' I have also known this company and some of its major researchers for a long time and I continue to believe that it has a very bright future. As a now retired company director in a totally different field, I have been in the same position, it's often difficult to grow at a rate that satisfies your shareholders! Stick with it.
17 Aug '14
It's all jam tomorrow for the company-except my experience is tomorrow never comes and I have known this company for at least 5 years-well before IPO and a shed load of funding rounds. Even with companies like this,'ground breaking' technology has to perform sooner or later and the evidence ain't helpful or supportive.
8 Aug '14
Good day to Mr Slimjim (and others)
For people who practice diversification, the past couple of weeks have not been very kind. I remember the point made in late July by Mr Slimjim: that he has chosen not to be diversified and that KMK is the share which suits him. I may not be able to know exactly why, but I got the feeling that he is a knowledgeable investor and that he did not arrive in hasty fashion at his opinion of KMK. So I was intrigued. I remain invested here, and it is nice to see an uptick today. I wish I had something significant to add about the company. I do not see many blue screens today. I suppose geopolitical concerns in the larger world are being seen in the investor community as inauspicious. In addition to KMK, one share that is showing blue quite nicely today is PYC. I wonder why. Maybe someone here follows that company. Lastly for the moment, two higher-priced shares that are on my radar screen are Hanger8 (symbol: HGR8) Caretech (symbol: CTH). I wonder whether anyone here has familiarity with either company. I am not involved in either, but I am debating with myself as to these companies. Good luck to quietly wise Mr Slimjim and to all. Rob
5 Aug '14
RE: Opportunity in Today's Drop?
I agree, the drop seems rather odd, especially off the back of the recent contract win. The fundamentals here seem good: very strong IP, an integrated supply/production chain( and at such an early stage!), and a decent run of orders; Hopefully the H1 results will not disappoint. In the long run I think Kromek has some fantastic IP, it really is world class technology. With any luck as the technology/market develops we will see the full potential of CZT tech!
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.